fluconazole has been researched along with ketamine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Berke, K; Joo, H; KuKanich, B; Orchard, R; Rankin, D | 1 |
| Barroso, FD; Cavalcanti, BC; da Silva, AR; da Silva, CR; da Silva, LJ; de Andrade Neto, JB; de Mesquita, JRL; de Moraes, MO; de Sá Carneiro, I; de Sousa Campos, R; do Amaral Valente Sá, LG; Nobre Júnior, HV; Queiroz, HA; S Aires do Nascimento, FB; Sampaio, LS | 1 |
1 review(s) available for fluconazole and ketamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fluconazole and ketamine
| Article | Year |
|---|---|
Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs.
Topics: Administration, Intravenous; Administration, Oral; Animals; Area Under Curve; Dogs; Drug Interactions; Female; Fluconazole; Half-Life; Ketamine; Male; Midazolam | 2019 |
6 other study(ies) available for fluconazole and ketamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synergistic effects of ketamine and azole derivatives on
Topics: Animals; Antifungal Agents; Biofilms; Candida; Candida albicans; Cell Survival; DNA Damage; DNA Fragmentation; DNA, Fungal; Drug Resistance, Fungal; Drug Synergism; Fluconazole; Itraconazole; Ketamine; L Cells; Membrane Potential, Mitochondrial; Mice; Microbial Sensitivity Tests; Microbial Viability; Phosphatidylserines; Reactive Oxygen Species | 2020 |